After making two sizable buys, Sanofi is moving ahead with a sale of its European generics business, according to multiple reports, and has narrowed down the field of potential buyers to drug companies from Brazil and India, plus several private equity funds, Reuters reports, citing sources.
Brazil’s EMS and Torrent Pharma have advanced to the next round of the process, according to the news service, along with a PE team of Blackstone and Nordic Capital, plus rival private equity firms Carlyle, BC Partners and Advent. The interested buyers are performing due diligence, the publication reports.
A source told the news service the competition could push up the price for a unit that might fetch $2.4 billion. Sanofi wants to find a buyer by the end of the quarter, according to Reuters.
For Sanofi, talk of the sale comes right on the heels of its $11.6 billion Bioverativ buy and its $4.8 billion Ablynx acquisition. Last year, the company made unsuccessful runs at Actelion and Medivation, but lost out in those pursuits to Johnson & Johnson and Pfizer, respectively.
Sanofi’s European generics business operates in 50 countries and sells drugs in disease areas including cardiovascular, central nervous system, gastrointestinal and metabolic disorders and more.
The drugmaker started talking about a sale for its European generics business way back in 2015, shortly after CEO Olivier Brandicourt took the helm and moved to reshape the company. After putting two units on the block, Brandicourt first focused on offloading Sanofi’s animal health unit Merial in a 2016 asset swap with Boehringer Ingelheim. In return, Sanofi picked up BI’s consumer health assets.
According to a recent report from India’s Economic Times, Aurobindo, Zydus Cadila, Torrent and Intas considered a buy for Sanofi’s European generics outfit, along with a Chinese drugmaker and private equity companies.
EMS and Torrent Pharma didn’t immediately respond to FiercePharma’s request for comment on the report. Sanofi declined to comment.
By Eric Sagonowsky
Source: Fierce Pharma
Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.
